Evidence map›Paper›PMID 39392046›Full record

ArticleJournal of the American Geriatrics Society2025

Physician-reported barriers and facilitators to thyroid hormone deprescribing in older adults.

Brandon Moretti, Rachel Livecchi, Stephanie R Taylor, Susan C Pitt, Brittany L Gay, Megan R Haymart, Arti Bhan, Jennifer Perkins, Maria Papaleontiou

Abstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Approach to the Patient Considering Thyroid Hormone Deprescribing.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. A Qualitative Study of Clinician Barriers and Facilitators to De-escalation of Thyroid Stimulating Hormone Suppression in Thyroid Cancer Survivors.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Article
  4. Considerations in the Diagnosis and Management of Thyroid Dysfunction in Older Adults.Thyroid : official journal of the American Thyroid Association · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brandon MorettiDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Rachel LivecchiDepartment of Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, Ohio, USA.
Stephanie R TaylorDivision of Endocrine Surgery, Department of General Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Susan C PittDivision of Endocrine Surgery, Department of General Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Brittany L GayDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Megan R HaymartDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Arti BhanDivision of Endocrinology, Diabetes, Bone and Mineral Disorders, Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan, USA.
Jennifer PerkinsDivision of Endocrinology and Metabolism, Department of Medicine and Surgery, University of California San Francisco, San Francisco, California, USA.
Maria PapaleontiouDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Funding

U.S. Deprescribing Research NetworkR24AG064025 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI BOYD, CYNTHIA MELINDA, STEINMAN, MICHAEL A. · 2019 to 2023
$9.9M
Optimizing Care for Older Adults through Thyroid Hormone DeprescribingR01AG079833 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAPALEONTIOU, MARIA · 2023 to 2024
$1.6M
The Effect of Inappropriate Use of Thyroid Hormone Replacement in Older MenK08AG049684 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAPALEONTIOU, MARIA · 2016 to 2022
$809k
NIA NIH HHS K08 AG049684NIA NIH HHS K08AG049684-S1NIA NIH HHS R01 AG079833NIA NIH HHS R01 AG079833-01A1NIA NIH HHS R24 AG064025University of MichiganU.S. Deprescribing Research Network Pilot Award R24AG-64025
6 · The paper itself

Abstract

backgroundThyroid hormone is one of the most commonly prescribed medications in the United States. Misuse of and overtreatment with thyroid hormone is common in older adults and can lead to cardiovascular and skeletal adverse events. Even though deprescribing can reduce inappropriate care, no studies have yet explored specific barriers and facilitators to guide thyroid hormone deprescribing in older adults (defined as discontinuation of thyroid hormone when initiated without an appropriate indication or dose reduction in those overtreated).

methodsWe conducted semi-structured interviews with 19 endocrinologists, geriatricians, and primary care physicians who prescribe thyroid hormone. Interviews were completed between July 2020 and December 2021 via two-way video conferencing. We used both an inductive and deductive content analysis guided by the Theoretical Domains Framework to evaluate transcribed and coded participant responses. Thematic analysis characterized themes related to barriers and facilitators to thyroid hormone deprescribing practices in older adults.

resultsThe most commonly reported barriers to thyroid hormone deprescribing were related to patient-level factors, followed by physician- and system-level factors. Patient factors included patients' perceived need for thyroid hormone use and patient anxiety/concerns about potential side effects related to thyroid hormone dose reduction, patient lack of knowledge, and misinformation regarding deprescribing. Physician- and system-level barriers included clinic visit time constraints, physician inertia, physician lack of knowledge about deprescribing, perceived lack of sufficient patient follow-up, and electronic health record limitations. The most prominent physician-reported facilitators to thyroid hormone deprescribing were effective physician-to-patient communication, and positive physician-patient relationship, including patients' trust in their treating physician.

conclusionBarriers and facilitators to thyroid hormone deprescribing in older adults were reported at multiple levels including patient-, physician-, and system-level factors. Interventions to improve thyroid hormone deprescribing in older adults should aim to improve patient education and expectations, increase multidisciplinary physician awareness, and overcome physician inertia.

Indexed as

DeprescriptionsPractice Patterns, Physicians'Thyroid HormonesAgedFemaleHumansInterviews as TopicMaleMiddle AgedQualitative ResearchUnited StatesThyroid Hormonesdeprescribinglow‐value careolder adultsthyroid hormone

Identifiers

PMID39392046
PMCPMC11828684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.